Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
5.76
+0.30 (5.46%)
Nov 5, 2024, 1:23 PM EST - Market open
Orchestra BioMed Holdings Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for OBIO stock have an average target of 15.75, with a low estimate of 14 and a high estimate of 20. The average target predicts an increase of 173.44% from the current stock price of 5.76.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 22, 2024.
Analyst Ratings
The average analyst rating for OBIO stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +143.06% | Aug 22, 2024 |
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +160.42% | Jul 25, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +247.22% | Jun 12, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +247.22% | Mar 28, 2024 |
| Jefferies | Jefferies | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +143.06% | Jan 19, 2024 |
Financial Forecast
Revenue This Year
2.97M
from 2.76M
Increased by 7.68%
Revenue Next Year
6.25M
from 2.97M
Increased by 110.40%
EPS This Year
-1.71
from -1.48
EPS Next Year
-1.80
from -1.71
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.6M | 15.3M | 3.9M | ||
| Avg | 3.0M | 6.3M | 3.3M | ||
| Low | 2.2M | 2.6M | 2.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 29.3% | 415.8% | -37.7% | ||
| Avg | 7.7% | 110.4% | -47.2% | ||
| Low | -21.6% | -11.3% | -56.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.68 | -1.60 | -1.80 | ||
| Avg | -1.71 | -1.80 | -1.74 | ||
| Low | -1.68 | -1.90 | -1.68 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.